BioSpace

BMS reports liver injury events in lung disease program, with key readout near

Bristol Myers Squibb will soon release Phase 3 data for admilparant that could make or break Contineum Therapeutics’ rival product. But reports of a death due to liver injury in the pharma’s program have caused some unease about the drug class.

Por BioSpace

1 minuto de lectura
Compartir
BMS reports liver injury events in lung disease program, with key readout near
BMS reports liver injury events in lung disease program, with key readout near

¿Tiene noticias que compartir con el sector de eventos?

Envíe un comunicado de prensa o una noticia y llegue a miles de profesionales del sector de eventos.

Contáctenos→

Más en Health Tech

Perspectivas relacionadas